Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05332925 · ClinicalTrials.gov registry record
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
A clinical trial of Lung Cancer and NSCLC, sponsored by Jun Zhang, MD, PhD.
- Recruiting
- Registry status
- 25
- Enrollment target
- 2
- Study locations
NCT05332925: Recruiting study of Lung Cancer and NSCLC, sponsored by Jun Zhang, MD, PhD.
NCT05332925 is a study of Lung Cancer and NSCLC that is actively recruiting participants, run by Jun Zhang, MD, PhD. The registered enrollment target is 25 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05332925, a study of Lung Cancer and NSCLC, is actively recruiting participants, sponsored by Jun Zhang, MD, PhD.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
Primary Outcome
Twenty-five patients will be enrolled. The bioassay will be considered to be feasible if the 3D Ex-Vivo assay results are obtained on at least 20 patients.
Conditions Studied
Interventions
- DRUG Standard of care immune checkpoint inhbitors
Study Locations (2)
Kansas
- The University of Kansas Cancer Center (KUCC) - Fairway
- The University of Kansas Cancer Center, Westwood Campus - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2027-02 |
What NCT05332925 shows while recruiting
NCT05332925 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Standard of care immune checkpoint inhbitors is the first listed.
NCT05332925 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT05332925 about?
NCT05332925 is a clinical study titled "Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC". To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
What is the current status of trial NCT05332925?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2022-07-21. Estimated completion is 2027-02.
What conditions does trial NCT05332925 study?
This clinical trial studies the following conditions: Lung Cancer, NSCLC, NSCLC Stage IV.
What interventions are being tested in trial NCT05332925?
The interventions under investigation include: Standard of care immune checkpoint inhbitors (DRUG).
Who is sponsoring clinical trial NCT05332925?
This trial is sponsored by Jun Zhang, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05332925 being conducted?
This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05332925's enrollment target sits among peer trials
25 335th of 409 higher than 72 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI